NWPF

News ArchivesRead News

Rave drug sparks hope for treating Parkinson’s

Wednesday June 20, 2012

bioscholar - Rave culture’s illicit drug ‘ecstasy’ can help develop drugs that curb involuntary movements in Parkinson’s disease, says a study.

A team led by a medicinal chemist at The University of Western Australia (UWA) studied the possibility. Matthew Piggott, associate professor, said Parkinson’s patients have a great deal of difficulty moving without medication.

The drug, levodopa, restores their movement but, over time, side-effects often develop. These include a reduction in therapeutic duration and jerky, involuntary movements known as dyskinesia.

“Dyskinesia is often confused as a symptom of Parkinson’s disease, when in fact it is a side-effect of the treatment,” Piggott was quoted as saying in the Journal of the Federation of American Societies for Experimental Biology.

“For some time now we’ve known that the drug most commonly sold as ‘ecstasy’, methylenedioxymethamphetamine (MDMA), ameliorates the side-effects of levodopa therapy. But MDMA has no therapeutic potential because it makes users ‘high’,” said Piggot, according to a university statement.

“Although controversial, there is also evidence that MDMA may be neurotoxic, or at least responsible for long-term, deleterious changes in brain chemistry,” Piggot said.

The team of UWA scientists, collaborating with Parkinson’s disease experts in Toronto, has now demonstrated that it is possible to de-link the beneficial effects of MDMA from its undesirable attributes. The feat was achieved through the creation of MDMA analogues – new compounds with a similar chemical structure to MDMA.

“The best compound, which we call UWA-101, is even more effective than MDMA at enhancing the quality of levodopa therapy,” said Piggot.

If translated to a medicine, this would mean that Parkinson’s patients could take their medication less frequently and get a better quality result from it,” Piggot added.

Disclaimer: Bioscholar is not intended to provide medical advice, diagnosis or treatment. The articles are based on peer reviewed research, and discoveries/products mentioned in the articles may not be approved by the regulatory bodies.

http://news.bioscholar.com/2012/06/rave-drug-sparks-hope-for-treating-parkinsons.html

Recent News

Jun 22 - A Confused Immune System Could Be Behind Parkinson's Disease
Jun 21 - Predicting cognitive deficits in people with Parkinson’s disease
Jun 13 - Brain Cell Transplants Are Being Tested Once Again For Parkinson's
Jun 12 - Smell Test May Sniff Out Oncoming Parkinson's and Alzheimer's
Jun 8 - Smartphones Track Motor Function in Parkinson's Disease
Jun 8 - GKC Enrolls First Patient in Personal KinetiGraph Trial as Part of NPF’s Parkinson’s Outcomes Project
Jun 8 - Low-fat dairy intake may raise Parkinson's risk
Jun 6 - Patient Voices: Parkinson's Disease
Jun 1 - World-First Trials Have Been Launched to Treat Parkinson's And Blindness With Embryonic Stem Cells
May 24 - Survival Rates Differ Widely in Parkinson's, MSA, Lewy Bodies
May 22 - Discovery may offer hope to Parkinson's disease patients
May 15 - Study offers answers on life expectancy for people with Parkinson's disease, Lewy body dementia
May 5 - Parkinson's in a dish: Researchers reproduce brain oscillations
May 5 - ‘Hunger Hormone’ Could Help Treat Parkinson’s Disease
May 3 - Antibiotic doxycycline may offer hope for treatment of Parkinson's disease
May 1 - Impulse Control Disorders in Parkinson's Disease: Building Physician, Patient Awareness
Apr 28 - Does Parkinson’s disease begin in the gut?
Apr 28 - New empathy-creating digital device could be revolutionary for caregivers
Apr 24 - Treating Depression With Deep Brain Stimulation Works—Most of the Time
Apr 24 - Parkinson’s disease shows links to depression